β2-Glycoprotein 1 Antibodies, IgM
Also known as: Anti-β2 Glycoprotein 1, Beta-2 Glycoprotein 1 Antibodies
Use
Assess the risk of thrombosis in patients who may be at risk for antiphospholipid syndrome (APS). This test should be used in conjunction with current traditional anticardiolipin and anticoagulant tests.1
Special Instructions
The test should be used in conjunction with other traditional anticardiolipin and anticoagulant tests to provide a comprehensive assessment for APS. It is not intended to be a standalone screening tool and should be interpreted in the context of clinical findings and other laboratory tests.
Limitations
Anti-β2-Glycoprotein 1 antibodies should not be used alone as a screening test for antiphospholipid syndrome. Discordant results are possible, with some patients testing positive for β2-GP1 antibodies but negative for other APS-associated markers. This could lead to false-negative APS diagnoses if only ACA or LA tests are utilized. Also, it is noted that ACA associated with infections tend not to be β2-GP1-dependent, and such results should be carefully interpreted in the context of clinical and laboratory findings.
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 16136-4
- 16136-4
Result Turnaround Time
2-3 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red-top tube or gel-barrier tube
Storage Instructions
Room temperature
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 15 days |
| Refrigerated | 15 days |
| Frozen | 15 days |
Other tests from different labs that may be relevant